Northwest Biotherapeutics (NWBO) Net Cash Flow (2010 - 2026)

Northwest Biotherapeutics' Net Cash Flow history runs 17 years deep, the most recent figure standing at -$3.4 million for Q1 2026.

• In Q1 2026, Net Cash Flow fell 254.32% year-over-year to -$3.4 million; the TTM figure through Mar 2026 stood at -$2.9 million (down 288.93% YoY), while the FY2025 annual figure was $2.7 million, up 320.63% from the prior year.
• Net Cash Flow for Q1 2026 stood at -$3.4 million, down from -$2.1 million in the prior quarter.
• The five-year high for Net Cash Flow was $5.5 million in Q2 2025, with the low at -$9.1 million in Q1 2022.
• The 5-year median for Net Cash Flow is -$560000.0 (2024), against an average of -$1.2 million.
• The sharpest annual moves came in 2023 and 2024: Net Cash Flow jumped 2662.04% in 2023, then tumbled 5700.0% in 2024.
• Northwest Biotherapeutics' Net Cash Flow stood at $342000.0 in 2022, then tumbled by 965.79% to -$3.0 million in 2023, then sank by 45.8% to -$4.3 million in 2024, then jumped by 51.8% to -$2.1 million in 2025, then plunged by 64.78% to -$3.4 million in 2026.
• Business Quant data shows NWBO's Net Cash Flow at -$3.4 million in Q1 2026, -$2.1 million in Q4 2025, and -$2.8 million in Q3 2025.